Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Raymond E
Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,
Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Baudin E, Wolin E, Castellano D, Kaltsas G, Lebrec J,
Keywords: mTOR, everolimus, octreotide, 5-hydroxyindoleacetic acid, 5-HIAA,
Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V,
Keywords: targeted therapy, sorafenib, bevacizumab,
Introduction: Duodenopancreatic neuroendocrine tumors (NETs) are uncommon neoplasms with a wide spectrum of clinical presentation. The infrequent occurrence of these tumors makes large experiences very scarce.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Martin-Perez E, Capdevila J, Castellano D, Jiménez-Lacave A, Beguiristain-Gómez A,
Keywords: pancreatic neuroendocrine tumors, gastrinoma, glucagonoma, insulinoma, registry, survival, treatment,